NCT04805333View on ClinicalTrials.gov

Phase 1 Dose Escalation of ArtemiCoffee

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

February 4, 2025

Study Completion Date

February 4, 2025

Conditions
Ovarian Cancer
Interventions
DRUG

Artemisia annua 450mg

Artemisia annua will be self-administered via a preparation of decaffeinated coffee.

DRUG

Artemisia annua 900mg

Artemisia annua will be self-administered via a preparation of decaffeinated coffee.

DRUG

Artemisia annua 1350mg

Artemisia annua will be self-administered via a preparation of decaffeinated coffee.

DRUG

Artemisia annua 1800mg

Artemisia annua will be self-administered via a preparation of decaffeinated coffee.

DRUG

Artemisia annua - recommended phase II dose

Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.

Trial Locations (1)

40536

University of Kentucky, Lexington

Sponsors

Collaborators (1)

ArtemiLife
All Listed Sponsors
collaborator

ArtemiLife

UNKNOWN

lead

Frederick R. Ueland, M.D.

OTHER